Table 3.
Type of Test utilized by the participant split by intervention and HPV result at 12 months and 18 months.a
| Follow-up | Phase 2 intervention | No test | Single test |
Both tests |
Total tested | Total | ||
|---|---|---|---|---|---|---|---|---|
| HPV only | Cytology only | HPV first | Cytology first | |||||
| 12 Months | Control | 3169 | 1 | 612 | – | – | 613 | 3782 |
| Self-samp. sent | 898 | 52 | 158 | 32 | 1 | 243 | 1141 | |
| Self-samp. off. | 1081 | 12 | 190 | 7 | – | 209 | 1290 | |
| Nurse nav. | 861 | – | 145 | 1 | – | 146 | 1007 | |
| Timed app. | 1306 | – | 323 | – | – | 323 | 1629 | |
| Choice | 1037 | 5 | 233 | 2 | – | 240 | 1277 | |
| Total | 8352 | 70 | 1661 | 42 | 1 | 1774 | 10,126 | |
| 18 Months | Control | 2756 | 1 | 1025 | – | – | 1026 | 3782 |
| Self-samp. sent | 799 | 59 | 248 | 34 | 1 | 342 | 1141 | |
| Self-samp. off. | 957 | 12 | 314 | 7 | – | 333 | 1290 | |
| Nurse nav. | 777 | – | 229 | 1 | – | 230 | 1007 | |
| Timed app. | 1157 | 1 | 471 | – | – | 472 | 1629 | |
| Choice | 892 | 5 | 378 | 2 | – | 385 | 1277 | |
| Total | 7338 | 78 | 2665 | 44 | 1 | 2788 | 10,126 | |
| Single test (%) |
Both tests (%) | |||||||
| Follow-up |
Phase 2 intervention | No test (%) | HPV only | Cytology only | HPV first | Cytology first | Total tested (%) | Total |
| 12 Months | Control | 3169(83.8) | 1(0.0) | 612(16.2) | – | – | 613(16.2) | 3782 |
| Self-samp. sent | 898(78.7) | 52(4.6) | 158(13.8) | 32(2.8) | 1(0.1) | 243(21.3) | 1141 | |
| Self-samp. off. | 1081(83.8) | 12(0.9) | 190(14.7) | 7(0.5) | – | 209(16.2) | 1290 | |
| Nurse nav. | 861(85.5) | – | 145(14.4) | 1(0.1) | – | 146(14.5) | 1007 | |
| Timed app. | 1306(80.2) | – | 323(19.8) | – | – | 323(19.8) | 1629 | |
| Choice | 1037(81.2) | 5(0.4) | 233(18.2) | 2(0.2) | – | 240(18.8) | 1277 | |
| Total | 8352(82.5) | 70(0.7) | 1661(16.4) | 42(0.4) | 1(0.0) | 1774(17.5) | 10,126 | |
| 18 Months | Control | 2756(72.9) | 1(0.0) | 1025(27.1) | – | – | 1026(27.1) | 3782 |
| Self-samp. sent | 799(70.0) | 59(5.2) | 248(21.7) | 34(3.0) | 1(0.1) | 342(30.0) | 1141 | |
| Self-samp. off. | 957(74.2) | 12(0.9) | 314(24.3) | 7(0.5) | – | 333(25.8) | 1290 | |
| Nurse nav. | 777(77.2) | – | 229(22.7) | 1(0.1) | – | 230(22.8) | 1007 | |
| Timed app. | 1157(71.0) | 1(0.1) | 471(28.9) | – | – | 472(29.0) | 1629 | |
| Choice | 892(69.9) | 5(0.4) | 378(29.6) | 2(0.2) | – | 385(30.2) | 1277 | |
| Total | 7338(72.5) | 78(0.8) | 2665(26.3) | 44(0.4) | 1(0.0) | 2788(27.5) | 10,126 | |
HPV: human papillomavirus.
a
Sixty-two women were within six days of 18 months follow-up and excluding these produced no change in the effect estimates or significance levels reported in Table 4.